Research shows mixed reactions to neurodiversity-friendly initiatives

Silent clapping, often referred to as “jazz hands,” is becoming popular as a way to make events more neurodivergent friendly. A new study from Karolinska Institutet shows that both neurodivergent and neurotypical people are generally positive towards the practice, although opinions vary widely. The study also highlights differing language preferences, with many participants indicating that…

Read More

The Emotional Aftermath of an Adult ADHD Diagnosis

Key points: Adult ADHD diagnoses often bring both relief and grief; both are well documented emotional responses. Because parenting intensifies emotional load, adult ADHD diagnoses affect the entire family system. Research shows that self-understanding in ADHD parents supports emotional regulation.

Read More

ADHD Symptoms Linked to Poor Glycemic Control in Adults With Type 1 Diabetes

Key Takeaways: Nearly one-third of surveyed adults with type 1 diabetes (T1D) screened positive for attention-deficit/hyperactivity disorder (ADHD) symptoms, far exceeding documented diagnosis rates. Positive ADHD screening was associated with more than double the odds of poor glycemic control (HbA1c ≥8.0%) and higher depression scores. No significant associations were observed between ADHD symptoms and most…

Read More

Alton Towers U-turns on plan to restrict disability pass

Merlin Entertainments has backtracked on its controversial plan to tighten access to its disability queuing system at its theme parks following strong criticism from people with autism, ADHD and anxiety. The company had planned to introduce new eligibility rules for its Ride Access Pass (RAP), which provides a non-queueing option for people unable to stand…

Read More

Lisdexamfetamine Dimesylate Oral Solution for ADHD to Be Available Mid-2026

Azurity Pharmaceuticals has announced that lisdexamfetamine dimesylate (Arynta) oral solution will be available mid-2026 for treating attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older.1 Arynta gained US Food and Drug Administration approval back on June 16, 2025, for the treatment of ADHD in adults and pediatric patients 6 years and…

Read More

Journal Digest: GLP-1s, Co-Occurring Borderline and ADHD, and More

Six in 10 Patients With Severe Borderline Personality Disorder Have Symptoms of ADHD Attention-deficit/hyperactivity disorder (ADHD) may be a common comorbid condition in patients with severe borderline personality disorder, a study in Psychiatric Research & Clinical Practice has found.

Read More